Cargando…

eIF5B increases ASAP1 expression to promote HCC proliferation and invasion

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide. Despite the therapeutic advances that have been achieved during the past decade, the molecular pathogenesis underlying HCC remains poorly understood. In this study, we discovered that increased expressio...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhen-guang, Zheng, Hao, Gao, Wei, Han, Jun, Cao, Jing-zhu, Yang, Yuan, Li, Shuai, Gao, Rong, Liu, Hui, Pan, Ze-ya, Fu, Si-yuan, Gu, Fang-ming, Xing, Hao, Ni, Jun-sheng, Yan, Hong-li, Ren, Hao, Zhou, Wei-ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308730/
https://www.ncbi.nlm.nih.gov/pubmed/27694689
http://dx.doi.org/10.18632/oncotarget.11469
Descripción
Sumario:Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide. Despite the therapeutic advances that have been achieved during the past decade, the molecular pathogenesis underlying HCC remains poorly understood. In this study, we discovered that increased expression eukaryotic translation initiation factor 5B (eIF5B) was significantly correlated with aggressive characteristics and associated with shorter recurrence-free survival (RFS) and overall survival (OS) in a large cohort. We also found that eIF5B promoted HCC cell proliferation and migration in vitro and in vivo partly through increasing ASAP1 expression. Our findings strongly suggested that eIF5B could promote HCC progression and be considered a prognostic biomarker for HCC.